Cardiovascular Effects of L-158,809, a New Angiotensin Type 1 Receptor Antagonist, Assessed Using the Halothane-Anesthetized In Vivo Canine Model.

DOI Web Site Web Site Web Site PubMed 被引用文献1件 参考文献26件

この論文をさがす

抄録

L-158,809 is a new angiotensin II type 1 receptor antagonist. We simultaneously assessed its antagonistic potency and cardiovascular effects with the halothane-anesthetized in vivo canine model (n = 5). L-158,809 was intravenously infused over 10 min at escalating doses of 0.03, 0.3 and 3 mg/kg. Angiotensin II (0.1 μg/kg, i.v.)-induced vasopressor and negative inotropic responses were significantly suppressed from the low dose L-158,809. Meanwhile, L-158,809 did not affect any of the cardiovascular parameters except that QTc was slightly shortened after the high dose administration. These results support the previous in vitro knowledge that L-158,809 is a highly selective angiotensin II receptor antagonist.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 89 (2), 192-196, 2002

    公益社団法人 日本薬理学会

被引用文献 (1)*注記

もっと見る

参考文献 (26)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ